Three of the most widely prescribed semaglutide drugs, Ozempic, Rybelsus, and Wegovy, are now linked to reports of sudden vision loss in one eye caused by a condition called non-arteritic anterior ischemic optic neuropathy, or NAION. The U.S. Food and Drug Administration flagged the connection in its October through December 2024 safety signal update and is evaluating whether regulatory action is needed. On June 27, 2025, the World Health Organization issued a safety communication directing health-care professionals and regulators worldwide to monitor patients taking semaglutide for this specific eye condition.
Why a rare eye condition is raising alarms for millions of semaglutide users
NAION strikes without warning. Blood flow to the optic nerve is suddenly cut off, typically in one eye, producing painless but often permanent vision loss. The condition has long been associated with risk factors such as diabetes, hypertension, and a crowded optic disc anatomy. What has changed is that multiple independent lines of evidence now point to semaglutide itself as a possible contributor, and the sheer number of people taking these drugs amplifies the stakes even if the absolute risk per patient stays low.
The FDA’s Adverse Event Monitoring System listed NAION as a potential safety signal for Ozempic, Rybelsus, and Wegovy and stated the agency is evaluating the need for regulatory action. That language places the signal in an active review pipeline rather than a closed investigation, meaning label changes, new warnings, or prescribing restrictions all remain on the table.
One question that regulators have not yet addressed publicly is whether certain comorbidities sharpen the risk. Obstructive sleep apnea, for instance, is already an established independent risk factor for NAION and is highly prevalent among people with obesity or type 2 diabetes, the same populations most likely to be prescribed semaglutide. If updated adverse-event extracts from the FDA’s FAERS database were stratified by sleep apnea diagnosis, the reporting odds ratio for NAION among semaglutide users with that comorbidity could prove measurably higher than among those without it. No published study has tested that specific interaction yet, leaving a gap that matters for clinical decision-making.
Three separate research efforts detected the same pharmacovigilance signal
The FDA signal did not emerge in isolation. A disproportionality study used the FAERS database to evaluate whether NAION reports are disproportionately associated with semaglutide compared with other drugs in the system. That analysis found a statistical signal strong enough to warrant further investigation, though disproportionality methods measure reporting patterns rather than proving direct causation.
A second, independent FAERS-based analysis reached a similar conclusion, characterizing the semaglutide–NAION relationship as an emerging pharmacovigilance signal. The fact that two separate research teams, working with the same adverse-event database but using their own analytic frameworks, arrived at consistent findings adds weight to the concern. Separately, a multinational population-based study published in the journal Ophthalmology analyzed NAION risk with semaglutide across real-world patient populations, broadening the evidence base beyond spontaneous adverse-event reports.
Global regulators have responded accordingly. The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee, known as PRAC, concluded that NAION is a very rare side effect of Ozempic, Rybelsus, and Wegovy. And the WHO’s safety communication from its Advisory Committee on Safety of Medicinal Products went a step further, concluding that the Risk Management Plan for semaglutide should be revised to include NAION as a potential risk. That recommendation, issued June 27, 2025, represents the most recent and most direct call for a formal change to how the drug’s risks are communicated to prescribers and patients.
What patients and prescribers still do not know about semaglutide and NAION
Several critical questions remain open. The FDA has not released patient-level case narratives or detailed outcome data from the NAION reports in its AEMS listing, so clinicians cannot yet assess how severe the vision loss was, whether it was reversible in any cases, or what dose and duration of semaglutide use preceded the event. The primary FAERS studies and the multinational analysis also lack published raw incidence rates or control-group demographics that would allow researchers to calculate absolute risk with confidence. Without those numbers, it is difficult to translate a pharmacovigilance signal into concrete guidance such as “one additional NAION case per X thousand patients treated.”
Another gap involves mechanisms. Researchers do not yet know why semaglutide might increase NAION risk in susceptible individuals. Hypotheses range from rapid shifts in blood pressure or blood glucose to drug-induced changes in small-vessel perfusion around the optic nerve. But none of these theories has been confirmed in controlled experiments. Until a plausible biological pathway is clarified, skeptics can reasonably argue that the association might reflect confounding by the underlying conditions-like diabetes and obesity-that already predispose people to optic nerve ischemia.
There are also unanswered questions about how risk might vary across formulations and dosing schedules. Ozempic and Wegovy are injectable, while Rybelsus is taken orally. Whether route of administration, titration speed, or maximum dose meaningfully alters NAION risk has not been established. Nor is it clear whether risk is concentrated in the first months of therapy or persists at a steady level over long-term use. Those details matter when clinicians weigh whether to continue a drug in someone who has already achieved substantial weight loss or glycemic control.
Regulators are still in the early stages of addressing these uncertainties. The FDA has placed NAION in its list of new safety information for semaglutide products, but has not yet mandated label changes. The WHO has urged national authorities to strengthen post-marketing surveillance and to report any additional NAION cases in patients taking semaglutide. How quickly those data will accumulate, and whether they will confirm or weaken the current signal, remains to be seen.
How clinicians can respond while evidence is still emerging
In the absence of definitive risk estimates, many experts suggest a precautionary approach focused on early recognition. Because NAION often presents as sudden, painless vision loss in one eye, patients starting semaglutide can be counseled to seek urgent ophthalmologic evaluation if they notice any abrupt change in vision, even if it seems minor or transient. Prompt assessment does not guarantee vision recovery, but it can help confirm the diagnosis, rule out other causes such as stroke or giant cell arteritis, and ensure the event is reported to pharmacovigilance systems.
For high-risk patients-those with prior NAION, significant optic disc crowding, or multiple vascular risk factors-clinicians may want to discuss the emerging evidence explicitly when considering semaglutide. That conversation can weigh the substantial benefits of the drug for weight loss and glycemic control against the small but potentially devastating possibility of vision loss. In some cases, alternative therapies or more gradual dose escalation might be reasonable compromises, though such strategies are not yet backed by controlled data.
Ophthalmologists, meanwhile, are being drawn into multidisciplinary care for patients on GLP-1 receptor agonists. Baseline eye exams may help document pre-existing optic nerve anatomy and vascular status, providing a reference point if symptoms develop later. Eye specialists can also help educate patients about what to watch for and ensure that suspected NAION cases are thoroughly documented and reported, adding to the global evidence base.
What patients should ask-and what comes next
For people already taking semaglutide, the emerging NAION signal does not mean they should abruptly stop treatment on their own. Discontinuing a drug that is effectively controlling diabetes or driving major weight loss can carry its own risks. Instead, patients can bring the issue to their next appointment and ask targeted questions: How high is my personal risk of NAION given my age and health history? Are there warning signs I should monitor? Would an eye exam be useful before continuing dose escalation?
As regulators digest new data from adverse-event reports, observational studies, and potentially randomized trials, guidance is likely to evolve. Label updates could eventually add NAION to the list of rare but serious adverse reactions, and risk management plans may incorporate more explicit ophthalmologic monitoring for certain patients. For now, the story of semaglutide and NAION is a reminder that even blockbuster therapies with well-established benefits can reveal unexpected risks once they reach millions of users-and that recognizing those risks early depends on vigilant reporting, careful analysis, and transparent communication with the people whose lives they affect.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
